CN112206232A - 治疗活性化合物的药物组合物及其用途 - Google Patents

治疗活性化合物的药物组合物及其用途 Download PDF

Info

Publication number
CN112206232A
CN112206232A CN202010472904.XA CN202010472904A CN112206232A CN 112206232 A CN112206232 A CN 112206232A CN 202010472904 A CN202010472904 A CN 202010472904A CN 112206232 A CN112206232 A CN 112206232A
Authority
CN
China
Prior art keywords
compound
pharmaceutical composition
use according
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010472904.XA
Other languages
English (en)
Chinese (zh)
Inventor
C-H.古
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of CN112206232A publication Critical patent/CN112206232A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ecology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202010472904.XA 2014-03-14 2015-03-13 治疗活性化合物的药物组合物及其用途 Pending CN112206232A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461953480P 2014-03-14 2014-03-14
US61/953,480 2014-03-14
CN201580019581.6A CN106163507B (zh) 2014-03-14 2015-03-13 治疗活性化合物的药物组合物及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580019581.6A Division CN106163507B (zh) 2014-03-14 2015-03-13 治疗活性化合物的药物组合物及其用途

Publications (1)

Publication Number Publication Date
CN112206232A true CN112206232A (zh) 2021-01-12

Family

ID=54072439

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010472904.XA Pending CN112206232A (zh) 2014-03-14 2015-03-13 治疗活性化合物的药物组合物及其用途
CN201580019581.6A Active CN106163507B (zh) 2014-03-14 2015-03-13 治疗活性化合物的药物组合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580019581.6A Active CN106163507B (zh) 2014-03-14 2015-03-13 治疗活性化合物的药物组合物及其用途

Country Status (28)

Country Link
US (1) US20170007661A1 (enExample)
EP (1) EP3116491B1 (enExample)
JP (3) JP6524119B2 (enExample)
KR (1) KR102458157B1 (enExample)
CN (2) CN112206232A (enExample)
AU (2) AU2015229212B2 (enExample)
BR (2) BR112016021012B1 (enExample)
CA (1) CA2942070A1 (enExample)
CY (1) CY1125205T1 (enExample)
DK (1) DK3116491T3 (enExample)
EA (2) EA202090098A1 (enExample)
ES (1) ES2881858T3 (enExample)
HR (1) HRP20211233T1 (enExample)
HU (1) HUE055209T2 (enExample)
IL (1) IL247721B (enExample)
LT (1) LT3116491T (enExample)
MA (1) MA39725B1 (enExample)
MX (2) MX2016011865A (enExample)
NZ (1) NZ723860A (enExample)
PH (1) PH12016501788B1 (enExample)
PL (1) PL3116491T3 (enExample)
PT (1) PT3116491T (enExample)
RS (1) RS62178B1 (enExample)
SI (1) SI3116491T1 (enExample)
SM (1) SMT202100444T1 (enExample)
UA (2) UA129317C2 (enExample)
WO (1) WO2015138837A1 (enExample)
ZA (1) ZA201606134B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9968595B2 (en) 2014-03-14 2018-05-15 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
UA123401C2 (uk) 2015-10-15 2021-03-31 Аджиос Фармасьютікалз, Інк. Комбінована терапія для лікування злоякісних пухлин
DK3362066T3 (da) 2015-10-15 2021-11-22 Les Laboratoires Servier Sas Kombinationsterapi til behandling af maligniteter
IL298663A (en) 2015-12-04 2023-01-01 Agios Pharmaceuticals Inc Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras
WO2017123808A1 (en) 2016-01-15 2017-07-20 The J. David Gladstone Institutes Methods of treating disease by metabolic control of t-cell differentiation
WO2017146795A1 (en) * 2016-02-26 2017-08-31 Agios Pharmaceuticals, Inc. Idh1 inhibitors for the treatment of haematological malignancies and solid tumours
WO2018085486A1 (en) * 2016-11-02 2018-05-11 University Of Cincinnati Compositions and methods for treating patients suffering from glioma or leukemia
JP2020506905A (ja) * 2017-01-20 2020-03-05 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． （ｒ）−ｎ−（（４−メトキシ−６−メチル−２−オキソ−１，２−ジヒドロピリジン−３−イル）メチル）−２−メチル−１−（１−（１−（２，２，２−トリフルオロエチル）ピペリジン−４−イル）エチル）−１ｈ−インドール−３−カルボキサミド固体分散液
HUE061207T2 (hu) 2017-09-22 2023-05-28 Chia Tai Tianqing Pharmaceutical Group Co Ltd Kristályos szulfamidvegyület
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
IL315423B1 (en) * 2018-07-06 2026-04-01 Servier Lab Ivusidnib forms and pharmaceutical preparations
US20210069113A1 (en) * 2019-09-11 2021-03-11 Modavar Pharmaceuticals LLC Solid unit dosage form for dose individualized drug delivery
TW202227446A (zh) 2020-08-12 2022-07-16 美商施維雅製藥有限公司 有機化合物之固態形式
CA3194380A1 (en) 2020-10-02 2022-04-07 Michael MORGEN Acetic acid as processing aid in spray drying for basic drugs
CN112022812B (zh) * 2020-11-03 2021-01-29 上海亚盛医药科技有限公司 一种包含杂环类化合物的组合物、其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100011610A1 (en) * 2006-12-22 2010-01-21 Vertex Pharmaceuticals Incorporated Fluidized spray drying
CN102827170A (zh) * 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US20130190249A1 (en) * 2012-01-19 2013-07-25 Agios Pharmaceuticals, Inc Therapeutically active compositions and their methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343548B2 (en) * 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US20100273808A1 (en) * 2008-11-21 2010-10-28 Millennium Pharmaceticals, Inc. Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
ES2740424T3 (es) * 2009-03-13 2020-02-05 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular
US20120238576A1 (en) * 2009-06-08 2012-09-20 California Capital Equity, Llc Triazine Derivatives and their Therapeutical Applications
US8652534B2 (en) * 2009-10-14 2014-02-18 Berry Pharmaceuticals, LLC Compositions and methods for treatment of mammalian skin
PL2630146T3 (pl) * 2010-10-21 2020-11-02 Medivation Technologies Llc Krystaliczna sól tosylanowa (8S,9R)-5-fluoro-8-(4-fluorofenylo)-9-(1-metylo-1H-1,2,4-triazol-5-ilo)-8,9-dihydro-2H-pirydo[4,3,2-de]ftalazyno-3(7H)-onu
LT2800743T (lt) * 2012-01-06 2018-06-25 Agios Pharmaceuticals, Inc. Terapiškai aktyvūs junginiai ir jų panaudojimo būdai
WO2014015422A1 (en) * 2012-07-27 2014-01-30 Ontario Institute For Cancer Research Cellulose-based nanoparticles for drug delivery
WO2015127173A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100011610A1 (en) * 2006-12-22 2010-01-21 Vertex Pharmaceuticals Incorporated Fluidized spray drying
CN102827170A (zh) * 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US20130190249A1 (en) * 2012-01-19 2013-07-25 Agios Pharmaceuticals, Inc Therapeutically active compositions and their methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
袁浩等: "胶质母细胞瘤与IDH1基因突变的关系", 《武汉大学学报(医学版)》 *

Also Published As

Publication number Publication date
RS62178B1 (sr) 2021-08-31
SI3116491T1 (sl) 2021-12-31
JP6524119B2 (ja) 2019-06-05
ZA201606134B (en) 2024-01-31
KR102458157B1 (ko) 2022-10-24
LT3116491T (lt) 2021-08-10
JP2021088605A (ja) 2021-06-10
PH12016501788A1 (en) 2016-12-19
EA034366B1 (ru) 2020-01-31
PT3116491T (pt) 2021-08-10
HRP20211233T1 (hr) 2021-10-29
DK3116491T3 (da) 2021-08-09
IL247721B (en) 2020-04-30
PH12016501788B1 (en) 2021-12-15
AU2019232825A1 (en) 2019-10-10
IL247721A0 (en) 2016-11-30
CN106163507A (zh) 2016-11-23
CY1125205T1 (el) 2023-03-24
BR122023021436A2 (pt) 2023-12-12
AU2019232825B2 (en) 2021-08-05
BR112016021012A2 (pt) 2018-08-07
UA122962C2 (uk) 2021-01-27
SMT202100444T1 (it) 2021-09-14
WO2015138837A1 (en) 2015-09-17
BR112016021012B1 (pt) 2024-01-23
AU2015229212B2 (en) 2019-06-20
NZ723860A (en) 2023-04-28
PL3116491T3 (pl) 2022-02-07
EA202090098A1 (ru) 2020-11-30
EP3116491A1 (en) 2017-01-18
JP2019163278A (ja) 2019-09-26
HUE055209T2 (hu) 2021-11-29
US20170007661A1 (en) 2017-01-12
JP2017508804A (ja) 2017-03-30
BR122023021440A2 (pt) 2023-12-12
KR20160124907A (ko) 2016-10-28
EA201691844A1 (ru) 2016-12-30
AU2015229212A1 (en) 2016-09-22
EP3116491B1 (en) 2021-05-05
MA39725B1 (fr) 2021-09-30
EP3116491A4 (en) 2017-11-15
CN106163507B (zh) 2020-06-26
ES2881858T3 (es) 2021-11-30
CA2942070A1 (en) 2015-09-17
MX2021001739A (es) 2021-04-19
UA129317C2 (uk) 2025-03-19
MX2016011865A (es) 2017-04-13

Similar Documents

Publication Publication Date Title
JP7801865B2 (ja) 治療活性化合物の医薬組成物
AU2019232825B2 (en) Pharmaceutical compositions of therapeutically active compounds
HK40044696A (en) Pharmaceutical compositions of therapeutically active compounds and uses thereof
HK40043528A (en) Pharmaceutical compositions of therapeutically active compounds
HK1233185B (en) Pharmaceutical compositions of therapeutically active compounds
BR122023021440B1 (pt) Composições farmacêuticas para tratar câncer
EA051161B1 (ru) Фармацевтические композиции терапевтически активных соединений

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210816

Address after: Fa Guoxuleineshi

Applicant after: LES LABORATOIRES SERVIER

Address before: Massachusetts, USA

Applicant before: AGIOS PHARMACEUTICALS, Inc.

TA01 Transfer of patent application right
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40044696

Country of ref document: HK